15 years ago, Sandoz launched the world’s first biosimilar! Biosimilars have unique potential to increase patient access, relieve mounting pressures on already overburdened healthcare systems and stimulate innovation. Despite proven benefits for patients and healthcare systems, biosimilar uptake still varies greatly not only between countries and therapy areas, but also within countries. We must create an environment that fosters greater biosimilar adoption and prepare for the next wave of biosimilars that will enter the market over the next decade.
To unlock the full potential of biosimilars, we need to take long-term oriented action now. Together, let’s unlock the full potential of biosimilars to ensure a successful future for patients, healthcare professionals and healthcare systems!
It’s been a long and exciting adventure since we launched the world’s first biosimilar in 2006. We asked several Sandoz associates these two questions:
How were things back THEN, when the first biosimilar was developed and launched?
15 years after the approval and launch of the world’s first biosimilar, where are we NOW?